In this free webinar, learn about metabolic- and alcohol-associated liver disease (MetALD) and alcohol-associated liver disease (ALD), focusing on the drug development pipeline. Attendees will gain insight into key outcome measures and development endpoints. The featured speakers will discuss adjacent diseases to MetALD and ALD (e.g., metabolic-dysfunction associated steatohepatitis [MASH]) that may offer mechanistic efficiencies for drug development.
TORONTO, May 12, 2025 /PRNewswire-PRWeb/ -- In this webinar, the leading experts in hepatology discuss metabolic- and alcohol-associated liver disease (MetALD) and alcohol-associated liver disease (ALD) focusing on the drug development pipeline, endpoints and key outcome measures. They will also explore related areas such as metabolic-dysfunction associated steatohepatitis (MASH) and metabolic-dysfunction associated steatotic liver disease (MASLD).
Alcohol is the most widely consumed substance in many countries. According to data from the US Centers for Disease Control, alcohol is responsible for approximately 178,000 deaths annually. Over half of US adults consume alcohol, with about 20 percent engaging in excessive drinking, which can result in severe health consequences.
It is widely known that alcohol consumption leads to liver complications, such as MetALD and ALD, both of which can progress to cirrhosis and its complications, including liver cancer, thus creating a significant unmet medical need for targeted drug development.
The clinical progression of MetALD and ALD typically starts with fat accumulation (steatosis), advancing to scaring (fibrosis) and potentially leading to alcoholic hepatitis, cirrhosis and ultimately liver failure. Each of these stages is associated with other health conditions, prompting drug development programs to focus on mechanistic targets and disease progression.
For instance, several ongoing development programs are targeted at treating MASH, including the 2024 approval of the first drug, Rezdiffra. MASH is defined by progression through various clinical features secondary to metabolic processes. Note that patients with excessive alcohol intake are excluded from MASH trials. Therefore, the medical community, including clinical trial sites, would benefit from conducting parallel studies in MetALD, ALD and MASH to improve screening efficiency while industry partners can de-risk their development strategies.
Despite the attraction for underlying liver histology, MetALD and ALD trials contain unique scientific and operational considerations. This webinar will address the current drug development pipeline for MetALD and ALD, including enrollment and retention challenges, clinical trial endpoints and key outcome measures, which will equip participants with insights that will drive innovation and collaboration in the ongoing fight against liver diseases.
Register for this webinar to advance the understanding of MetALD/ALD and the clinical trial landscape.
Join Dr. Mazen Noureddin, Chief Scientific Officer, Summit Clinical Research; Dr. Naim Alkhouri, MD, Chief Academic Officer, Summit Clinical Research; Dr. Brian Lee, MD, Associate Professor of Clinical Medicine, USC; and Dr. Juan Pablo (JP) Arab, Associate Professor of Medicine, Virginia Commonwealth University, for the live webinar on Friday, May 23, 2025, at 11am EDT (5pm CEST/EU-Central).
For more information, or to register for this event, visit Metabolic and Alcohol Associated Liver Disease (MetALD/ALD): An Emerging Drug Development Field.
ABOUT XTALKS
Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars and digital content to the global life science, food, healthcare and medical device communities. Every year, thousands of industry practitioners (from pharmaceutical, biotechnology, food, healthcare and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps professionals stay current with industry developments, regulations and jobs. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.
To learn more about Xtalks visit https://xtalks.com
For information about hosting a webinar visit https://xtalks.com/why-host-a-webinar/
Contact:
Vera Kovacevic
Tel: +1 (416) 977-6555 x371
Email: [email protected]
Media Contact
Vera Kovacevic, Xtalks, +1 (416) 977-6555 x371, [email protected], www.xtalks.com
SOURCE Xtalks
Share this article